Financials
Financial year 2025
MEDIGROUP from Anderlecht, company number BE0826773857, closed financial year 2025 with a result of € -201,774 after tax. For that financial year MEDIGROUP recorded a gross margin of € 720,134 and equity of € 23.7 million. Compared with financial year 2024, the result moved from € 3.9 million to € -201,774. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.
€ 23.7 million
▼ 1% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -201,774
▼ still € 3.9 million profit in 2024
Profit after tax over the fiscal year.
€ 502,317
▲ € 431,118 vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 14.6 million.
People and assets in 2025
14.1
▲ 0.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.6 million
▲ 25% vs 2024
€ 116,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 392,479
▲ 17% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 495,746
▼ 20% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,645,042 | € 1,489,734 | € 1,989,825 | € 720,134 | ▼ 64% |
| Profit after taxes | € 879,561 | € 1,894,451 | € 3,852,111 | € -201,774 | ▼ € 4.1 million |
| Equity | € 42,145,350 | € 44,039,801 | € 23,891,912 | € 23,690,139 | ▼ 1% |
| Total debts | € 5,943,861 | € 4,382,472 | € 5,663,130 | € 6,487,774 | ▲ 15% |
| Cash | € 112,122 | € 96,044 | € 71,199 | € 502,317 | ▲ € 431,118 |
| Retained profit | € 33,076,840 | € 34,971,291 | € 14,823,402 | € 14,621,629 | ▼ 1% |
| Dividend | € 0 | € 0 | € 24,000,000 | € 0 | ▼ 100% |
| Balance sheet total | € 48,089,211 | € 48,422,274 | € 29,555,043 | € 30,177,913 | ▲ 2% |
| Employees (FTE) | 13.9 | 12.2 | 13.5 | 14.1 | ▲ 0.6 |
Key figures of MEDIGROUP, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MEDIGROUP?
What happened at MEDIGROUP in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Nikka Management BV stepped down as director. NBB
- Jordan Chir stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 201,774 (▼ € 4.1 million vs 2024). Source: NBB ↗
- Themtis BV stepped down as director. NBB
- Jordan Chir became a director. NBB
- LMDC GmbH stepped down as director. NBB
- Themtis BV became a director. NBB
- Nikka Management BV became a director. NBB
In short
From € 879,561 profit in 2022 to € 201,774 loss in 2025.
Paid € 588,472 in corporate taxes since 2022.
Best year ever: 2024, with € 3.9 million profit.
On average € 51,100 of value added per employee in 2025.
A new publication or filing at MEDIGROUP? We notify you, reason included.
Follow MEDIGROUPDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of A.forall Group comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
MEDIGROUPThe shares are held by A.forall Group (100%). It owns 100% of Beta Active PI Pharma Ltd, 100% of Eco.Pharma.Supply, 100% of PI PHARMA, 100% of Impexeco and 100% of Eco Pharma Supply Distribution itself.
Directors
According to the 2025 annual accounts
Director · represented by Filip Van de Vliet
Also active at: ECOPHARMASUPPLY DISTRIBUTION, ECO.PHARMA.SUPPLY, FYTEKO, A.forall Group, A.forall Development
since 2025 · until 2025
since 2025 · until 2031
since 2025 · until 2031
LMDC GmbH
Director · represented by Libor Matyasek
Also active at: ECOPHARMASUPPLY DISTRIBUTION, IMPEXECO, ECO.PHARMA.SUPPLY, PI PHARMA
since 2025 · until 2025
Shareholders
100%
Participations
Beta Active PI Pharma Ltd
100%
100%
100%
100%
Establishments
Establishment units
Physical locations of this company
Marie Curiesquare 50
1070 Anderlecht
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 5 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0826.773.857
- VAT number
- BE 0826.773.857
- Registered office
- Marie Curiesquare 50, 1070 Anderlecht
- Names & denominations
- MEDIGROUP
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 18 June 2010
- Peppol
- Active · Active since 6 Jan 2026
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Groothandel in farmaceutische en medische artikelen
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Activiteiten van hoofdkantoren